Eloxx doses first patients in Phase 2b EXACT trial of exaluren for nonsense mutation Alport syndrome

PUBT · 1d ago
Eloxx doses first patients in Phase 2b EXACT trial of exaluren for nonsense mutation Alport syndrome
  • Eloxx Pharmaceuticals began dosing patients in the Phase 2b EXACT trial of exaluren for nonsense mutation Alport syndrome.
  • Topline results from the initial 16-week placebo-controlled portion are expected in mid-2027.
  • A final study readout is targeted for the end of 2027.
  • The trial aims to evaluate whether exaluren can address the underlying genetic cause of the disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eloxx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609110730PR_NEWS_USPR_____NE45671) on September 11, 2026, and is solely responsible for the information contained therein.